The phase III AVATAR trial investigated the efficacy of the addition of bevacizumab (anti-vascular endothelial growth factor agent) to chemotherapy (CX regimen) as first-line treatment in 202 Asian patients with metastatic GC [95]. This evidence concerns the gene VEGFA and gastric cancer.